LDHA@MIP-DSD is designed to inhibit LDHA activity, effectively deactivating TAFs and enhancing the ability of therapeutic agents to penetrate the tumor stroma, thereby gaining access to cancer cells. The gene discussed is LDHA; the disease is neoplasm.